Skip to content

Latest commit

 

History

History
63 lines (45 loc) · 5.33 KB

README.md

File metadata and controls

63 lines (45 loc) · 5.33 KB
Raw

Diabetes mellitus type 2 mortality prevention with pharmacotherapy

A living systematic review with arrows plot

Short url: http://openMetaAnalysis.github.io/Diabetes-mellitus-type-2-mortality-prevention-with-pharmacotherapy

Clinical summary: This meta-analysis suggests that clinical intervention is not effective. Heterogeneity of results as measured by I2 was 'moderate' at 64%. This review updates the previously published meta-analysis.(1)

Mortality reduction is shown in the subgroups of trials that used sodium glucose transporter 2 (SGLT2) inhibitors or GLP-1 receptor agonists.

Acknowledgement: we acknowledge the essential work by the authors of the prior systematic review(s) listed below.

Methods overview: This repository is an openMetaAnalysis that combines methods of scoping, rapid, and living systematic reviews. This analysis updates one or more previously published review(s).(1) A comparison of studies include in this review compared to prior reviews are in the table, reconciliation of trials included with prior meta-analyses/. Newer studies included are listed in the references below. Rationale for newer trials excluded may be listed at the end of the references.

Results: Details of the studies included are in the:

The forest plot for the primary outcomes are below. Additional forest-plots of secondary analyses may be available. Principle results

The arrows plot for the primary outcomes are below. Additional arrows-plots of secondary analyses may be available. Principle results

The meta-regression for the primary outcomes are below. Additional metaregressions of secondary analyses may be available. Principle results for benefit

References:

Systematic review(s)

Most recent review at time of last revision of this repository

  1. Huang CJ, Wang WT, Sung SH, Chen CH, Lip GYH, Cheng HM, Chiang CE. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342. PMID: 29722116
  2. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024. PMID: 29677303
  3. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M,et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. PMID: 21791495

Randomized controlled trials

New trial(s) not included in the most recent review above

None

Trial(s) included in the review above

None

Trial(s) undergoing review

None

Trial(s) excluded - selected list of important trial(s)

Cited by

This repository is cited by:

  1. WikiDoc contributors. Diabetes mellitus type 2 medical therapy. WikiDoc. June 11, 2018. Available at: https://www.wikidoc.org/index.php/Diabetes_mellitus_type_2_medical_therapy. Accessed June 11, 2018.
  2. Badgett RG, Dong F, Aung K. Arrow plot: a display for results of meta-analyses of surrogate and clinical outcomes. BMJ 2011. Available at https://www.bmj.com/rapid-response/2011/11/03/arrow-plot-display-results-meta-analyses-surrogate-and-clinical-outcomes. Accessed June 11, 2018.

Cite and use this content - Edit this page - History - Issues and comments